Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Changes in overactive bladder symptoms after withdrawal of solifenacin following initial 12-week combination therapy with tamsulosin in men with benign prostatic hyperplasia and overactive bladder
KCT0000392Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- Apr 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of solifenacin in benign prostatic hyperplasia (BPH), overactive bladder (OAB), sponsored by Astellas Pharma. Started Apr 2009; status: completed.
02
Drugs
solifenacin
03
Conditions
benign prostatic hyperplasia (BPH)overactive bladder (OAB)
Beyond the preview
Go deeper on KCT0000392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000392.